Affordable Access

Access to the full text

Targeting ARID1A-Deficient Cancers: An Immune-Metabolic Perspective

Authors
  • lebedev;, li timofey
Publication Date
Mar 21, 2023
Identifiers
DOI: 10.3390/cells12060952
OAI: oai:mdpi.com:/2073-4409/12/6/952/
Source
MDPI
Keywords
Language
English
License
Green
External links

Abstract

Epigenetic remodeling and metabolic reprogramming, two well-known cancer hallmarks, are highly intertwined. In addition to their abilities to confer cancer cell growth advantage, these alterations play a critical role in dynamically shaping the tumor microenvironment and antitumor immunity. Recent studies point toward the interplay between epigenetic regulation and metabolic rewiring as a potentially targetable Achilles’ heel in cancer. In this review, we explore the key metabolic mechanisms that underpin the immunomodulatory role of AT-rich interaction domain 1A (ARID1A), the most frequently mutated epigenetic regulator across human cancers. We will summarize the recent advances in targeting ARID1A-deficient cancers by harnessing immune-metabolic vulnerability elicited by ARID1A deficiency to stimulate antitumor immune response, and ultimately, to improve patient outcome.

Report this publication

Statistics

Seen <100 times